ALX Oncology (ALXO) Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/18/2026

1. VRNS
2. CRWV
3. JBHT
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. AA
10. TECHM:IN

Go back to ALX Oncology (ALXO) Provides Corporate Update

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023

January 5, 2023 7:00 AM EST

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestones anticipated in 2023.

2022 marked a successful year of continued clinical and corporate accomplishments for ALX Oncology. Marked by steady progress in the clinical development of our lead program, evorpacept, for the treatment of multiple solid tumor indications and hematological malignancies, we expanded clinical development of evorpacept in new indications and combinations. These included a Phase 1 trial in... More